Copied to clipboard!
High prevalence of CHIP after 177Lu-DOTA-TATE
In Neuroendocrine tumors (NETs), 177Lu-DOTA-TATE peptide receptor radionuclide therapy (PRRT) has demonstrated efficacy but significant hematologic toxicity, including therapy-related myeloid neoplasms (t-MN). Here, we assessed the prevalence of clonal hematopoiesis (CHIP), a known risk factor for therapy-related myeloid neoplasms (t-MN), according to previous PRRT exposure.
- Type: Cancer Genomics
- Archive: European Genome-phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD50000003135 | Illumina MiSeq NextSeq 500 NextSeq 550 | 152 |
